Literature DB >> 23229814

Omalizumab: NICE to USE you, to LOSE you NICE.

Andy Bush, Ian D Pavord.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23229814     DOI: 10.1136/thoraxjnl-2012-202969

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  6 in total

Review 1.  Severe asthma: definition, diagnosis and treatment.

Authors:  Marek Lommatzsch; J Christian Virchow
Journal:  Dtsch Arztebl Int       Date:  2014-12-12       Impact factor: 5.594

Review 2.  Rationale and clinical results of inhibiting interleukin-5 for the treatment of severe asthma.

Authors:  Rachid Berair; Ian D Pavord
Journal:  Curr Allergy Asthma Rep       Date:  2013-10       Impact factor: 4.806

Review 3.  Newer treatments in the management of pediatric asthma.

Authors:  Paul D Robinson; Peter Van Asperen
Journal:  Paediatr Drugs       Date:  2013-08       Impact factor: 3.022

4.  Against all odds: anti-IgE for intrinsic asthma?

Authors:  Marek Lommatzsch; Stephanie Korn; Roland Buhl; Johann Christian Virchow
Journal:  Thorax       Date:  2013-05-24       Impact factor: 9.139

Review 5.  Novel strategies for the treatment of asthma.

Authors:  Marek Lommatzsch; Paul Stoll
Journal:  Allergo J Int       Date:  2016-02-11

6.  How patient participation was used to develop a questionnaire that is fit for purpose for assessing quality of life in severe asthma.

Authors:  Michael E Hyland; Joseph W Lanario; Jill Pooler; Matthew Masoli; Rupert C Jones
Journal:  Health Qual Life Outcomes       Date:  2018-01-27       Impact factor: 3.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.